Category: Hiv care

A 2006 clinical trial known as the SMART study demonstrated that people who received intermittent antiretroviral treatment experienced double the rate of disease progression compared to those on continuous therapy. This evidence strongly underscores why you must never ask, 'Can I stop taking Reydin?' without first speaking to your healthcare provider.

Lenacapavir is a first-in-class, long-acting HIV capsid inhibitor administered as a twice-yearly injection, a significant advancement in HIV care. Understanding who qualifies for lenacapavir is crucial, as eligibility depends on its intended use for either prevention (PrEP) or treating multi-drug resistant HIV.